<< Read Full Article
<< Read Full Article
An experimental pill from Incyte(INCY Quote) reduced symptoms in rheumatoid arthritis patients, according to results from a small phase II study presented Sunday.
Incyte, a small Delaware-based drugmaker, is one of several entrants in a race to develop the first oral drug for rheumatoid arthritis (RA). The prize is a multibillion-dollar market for the company that can develop a pill that is as effective as and safer than current treatments, all of which must be given by injection.
Results from a 28-day midstage study of Incyte's experimental pill, INCB18424, were presented Sunday at the American College of Rheumatology annual meeting. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,388.90 | 1,105.98 | 2,194.35 | 34.83 |
Oil *
77.74
|
|
UP
22.75
|
UP
6.06
|
UP
21.21
|
UP
1.03
|
10 Yr
3.48%
SPDR Gold
113.75
|
|
+0.22%
|
+0.55%
|
+0.98%
|
+3.05%
|
Data delayed 20 minutes |
Connect with TheStreet